Levetiracetam

How Does Levetiracetam Work?

Levetiracetam works through a novel mechanism that is fundamentally different from all older antiepileptic drugs. Its primary target is the synaptic vesicle glycoprotein SV2A—a protein found on the surface of synaptic vesicles (the tiny packets that store neurotransmitters inside nerve cells). By binding to SV2A, levetiracetam modulates how vesicles release neurotransmitters during high-frequency neuronal firing, selectively dampening the abnormal, synchronized bursts of activity that characterize seizures.

Unlike older AEDs such as phenytoin, carbamazepine, or valproic acid, levetiracetam does NOT inhibit voltage-gated sodium channels, does NOT affect GABA receptors, and does NOT bind to glutamate receptors. This unique, non-overlapping mechanism explains why it is effective for patients who don't respond to other AEDs and why it has so few drug interactions. Levetiracetam also inhibits presynaptic calcium channels, providing an additional brake on excessive neurotransmitter release.

Pharmacokinetically, levetiracetam is nearly ideal: it has close to 100% oral bioavailability, is minimally protein-bound (<10%), is not significantly metabolized by the liver (66% excreted unchanged by the kidneys), and has few drug-drug interactions. Plasma half-life is 6–8 hours; steady-state is reached in just 2 days. Dose adjustment is required for renal impairment.

How Hard Is It to Find Levetiracetam in Stock?

As of 2026, there is no active national FDA shortage of oral levetiracetam immediate-release tablets in the United States. Generic levetiracetam is produced by multiple manufacturers including Apotex, Lupin, Torrent, Sun Pharma, and Teva, providing redundancy in the supply chain. The findability score of 72/100 reflects that while the medication is generally available, localized spot shortages at individual pharmacy locations remain common.

Levetiracetam has a history of supply disruptions: the most significant national shortage occurred in 2019–2020, when the FDA listed multiple generic manufacturers as having supply issues. The injectable formulation experienced documented supply issues in 2024. UK patients faced branded tablet shortages into early 2025. A 2024 survey found 62.8% of epilepsy patients had experienced difficulty finding levetiracetam—a figure that substantially exceeds what national shortage data would suggest, reflecting the impact of local spot shortages.

If your pharmacy is out of levetiracetam, medfinder can call pharmacies near you to find which ones have your specific medication in stock—saving you hours of phone calls and preventing dangerous medication gaps.

Who Can Prescribe Levetiracetam?

Levetiracetam is not a controlled substance, so there are no DEA-based prescribing restrictions. Any licensed prescriber can write a prescription, and it can be filled at any licensed pharmacy without schedule-related limitations. For new epilepsy diagnoses, a neurologist is strongly recommended; for established patients with well-controlled seizures, primary care providers commonly manage ongoing refills.

• Neurologists — specialist of choice for new diagnoses and complex epilepsy management
• Epileptologists — neurologists with subspecialty epilepsy training; best for complex cases
• Pediatric neurologists — for children with epilepsy
• Primary care physicians (PCPs) — for established patients with stable, well-controlled epilepsy
• Nurse practitioners (NPs) and Physician assistants (PAs) — can prescribe independently or under physician supervision in most states

Telehealth is available for established patients needing follow-up visits and prescription refills. Since levetiracetam is not a controlled substance, telehealth prescribing does not require in-person visits under current federal regulations. A new seizure diagnosis, however, typically requires in-person evaluation including EEG and MRI before initiating treatment.

Is Levetiracetam a Controlled Substance?

No. Levetiracetam is not a controlled substance under U.S. federal law. It has no DEA scheduling (Schedule I through V). It does not have recognized abuse potential, does not cause physical dependence in the way controlled substances do, and is not associated with euphoria or misuse.

This means there are no federal restrictions on the number of refills, no requirement for paper prescriptions, no limits on early refills based on DEA rules, and no restrictions on transferring the prescription between pharmacies. Any licensed prescriber can prescribe levetiracetam without DEA authorization. Patients can fill it at any licensed pharmacy. This non-controlled status is a practical advantage when dealing with local stock-outs—patients can simply move their prescription to a pharmacy that has it.

Common Side Effects of Levetiracetam

Common side effects (occurring in more than 5% of patients in clinical trials):

• Somnolence / drowsiness (14%)
• Headache (14%)
• Asthenia / weakness (15% in adults)
• Dizziness
• Irritability, aggression, mood changes ("Keppra rage") — affects 5–15% of patients
• Nasopharyngitis / infection
• In children: fatigue, aggression, nasal congestion, decreased appetite

Serious Side Effects (Seek Immediate Medical Attention)

• DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): Rare; starts as rash 2–8 weeks after initiation; can progress to life-threatening organ damage. FDA safety alert issued December 2023.
• Stevens-Johnson syndrome / Toxic Epidermal Necrolysis: Rare but life-threatening skin reactions. Stop medication immediately if blistering rash develops.
• Suicidal thoughts or behavior: Class warning for all AEDs. Seek help immediately for new or worsening depression.
• Anaphylaxis / angioedema: Can occur after the first dose. Call 911 for swelling of face/throat or difficulty breathing.
• Psychosis / hallucinations: Occurs in about 1% of adults and 2% of children. Notify prescriber immediately.

Final Thoughts on Levetiracetam

Levetiracetam remains one of the most important antiepileptic drugs in modern epilepsy treatment. Its novel mechanism of action (SV2A binding), favorable pharmacokinetic profile, low drug interaction burden, non-controlled status, and wide age range of approval make it a versatile first- and second-line option for most seizure types. Generic availability since 2008 has made it accessible to patients at price points as low as $6 per month with discount coupons.

The main challenges with levetiracetam are behavioral side effects (irritability, aggression—the so-called "Keppra rage") in 5–15% of patients, and the risk of rare but serious reactions including DRESS and Stevens-Johnson syndrome. Patients and caregivers should be counseled on these risks at initiation. Never stop levetiracetam abruptly—always taper under physician guidance.

If you're having trouble finding levetiracetam at your local pharmacy, medfinder can help. medfinder calls pharmacies near you to find which ones have your medication in stock—so you can focus on managing your health, not hunting for your prescription.